1. Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211-59.

https://doi.org/10.1016/S0140-6736(17)32154-2

PMid:28919117

2. Coleman RE, Roodman, Smith, Body, Suva, Vessella. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s-9s.

https://doi.org/10.1158/1078-0432.CCR-06-0931

PMid:17062708 

3. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab. J Oral Maxillofac Surg. 2010;68:959-63.

https://doi.org/10.1016/j.joms.2009.10.010

PMid:20149510 PMCid:PMC2880179

4. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48:221-3.

https://doi.org/10.1016/j.bjoms.2009.08.030

PMid:19836866 

5. Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:671-6.

https://doi.org/10.1016/j.oooo.2012.08.439

PMid:23159111 

6. Bagan L, Jimenez Y, Leopoldo M, Murillo-Cortes J, Bagan J. Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics. Med Oral Patol Oral Cir Bucal. 2017;22:e582-5.

https://doi.org/10.4317/medoral.22133

PMid:28809382 PMCid:PMC5694180

7. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw -- 2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.

https://doi.org/10.1016/j.joms.2014.04.031

PMid:25234529 

8. King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab - a review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127:289-99.

https://doi.org/10.1016/j.oooo.2018.11.012

PMid:30713092 

9. Yamagata K, Nagai H, Baba O, Uchida F, Kanno N, Hasegawa S, et al. A Case of Brain Abscess Caused by Medication-Related Osteonecrosis of the Jaw. Case Rep Dent. 2016;2016:7038618.

https://doi.org/10.1155/2016/7038618

PMid:26949551 PMCid:PMC4754463

10. Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of Osteonecrosis of the Jaws. Oral Maxillofac Surg Clin North Am. 2015;27:489-96.

https://doi.org/10.1016/j.coms.2015.06.001

PMid:26412796 PMCid:PMC4908822

11. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018;24:527-36.

https://doi.org/10.1111/odi.12708

PMid:28656643 

12. Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. Stem Cells Int. 2016;2016:8768162.

https://doi.org/10.1155/2016/8768162

PMid:27721837 PMCid:PMC5046039

13. Zheng GZ, Chang B, Lin FX, Xie D, Hu QX, Yu GY, et al. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. Eur J Cancer Care (Engl). 2017;26:1-7.

https://doi.org/10.1111/ecc.12541

PMid:27430483 

14. Hortobagyi GN, Zheng M, Mohanlal R. Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. Oncologist. 2019;24:178-84.

https://doi.org/10.1634/theoncologist.2018-0218

PMid:30297386 PMCid:PMC6369945

15. Van Den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): Non bis in idem? Support Care Cancer. 2011;19:2035-40.

https://doi.org/10.1007/s00520-010-1061-0

PMid:21203781 

16. Qi W-X, Tang L-N, He A-N, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19:403-10.

https://doi.org/10.1007/s10147-013-0561-6

PMid:23605142 

17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8:336-41.

https://doi.org/10.1016/j.ijsu.2010.02.007

PMid:20171303 

18. Zintzaras E, Ioannidis JPA. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123-37.

https://doi.org/10.1002/gepi.20048

PMid:15593093 

19. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380-2.

https://doi.org/10.1016/j.jclinepi.2010.09.011

PMid:21185693 

20. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

https://doi.org/10.1136/bmj.d5928

PMid:22008217 PMCid:PMC3196245

21. Ockerman A, Bornstein MM, Leung YY, Li SKY, Politis C, Jacobs R. Incidence of bleeding after minor oral surgery in patients on dual antiplatelet therapy: a systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2019;49:90-8.

https://doi.org/10.1016/j.ijom.2019.06.002

PMid:31248706 

22. Anzures-Cabrera J, Higgins JPT. Graphical displays for meta-analysis: An overview with suggestions for practice. Res Synth Methods. 2010;1:66-80.

https://doi.org/10.1002/jrsm.6

PMid:26056093 

23. Bax L, Yu L-M, Ikeda N, Tsuruta H, Moons KGM. Development and validation of MIX: Comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:50.

https://doi.org/10.1186/1471-2288-6-50

PMid:17038197 PMCid:PMC1626481

24. Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, De Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 2010;28:5132-9.

https://doi.org/10.1200/JCO.2010.29.7101

PMid:21060033 

25. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377:813-22.

https://doi.org/10.1016/S0140-6736(10)62344-6

PMid:21353695

26. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-32.

https://doi.org/10.1200/JCO.2010.31.3304

PMid:21343556 

27. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082-92.

https://doi.org/10.1016/j.ejca.2012.08.002

PMid:22975218 

28. Scagliotti G V, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7:1823-9.

https://doi.org/10.1097/JTO.0b013e31826aec2b

PMid:23154554 

29. Henry D, Vadhan-Raj S, Hirsh V, Von Moos R, Hungria V, Costa L, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of data from patients with solid tumors. Support Care Cancer. 2014;22:679-87.

https://doi.org/10.1007/s00520-013-2022-1

PMid:24162260 

30. Stopeck AT, Fizazi K, Body J-J, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24:447-55.

https://doi.org/10.1007/s00520-015-2904-5

PMid:26335402 PMCid:PMC4669370

31. Stopeck AT, Fizazi K, Body J-J, Brown JE, Carducci M, Diel I, et al. Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24:447-55.

https://doi.org/10.1007/s00520-015-2904-5

PMid:26335402 PMCid:PMC4669370

32. Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19:370-81.

https://doi.org/10.1016/S1470-2045(18)30072-X

PMid:29429912

33. Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belgica Int J Clin Lab Med. 2018;73:100-9.

https://doi.org/10.1080/17843286.2017.1348001

PMid:28693379 

34. Karna H, Gonzalez J, Radia HS, Sedghizadeh PP, Enciso R. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses. Oral Oncol. 2018;85:15-23.

https://doi.org/10.1016/j.oraloncology.2018.08.003

PMid:30220314 

35. Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, et al. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:440-5.

https://doi.org/10.1016/j.oooo.2018.02.003

PMid:29580668 

36. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiødt M, Klinge B. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clin Oral Implants Res. 2018;29:54-92.

https://doi.org/10.1111/clr.13282

PMid:30306695